Symptomatic remission affects employment outcomes in schizophrenia patients

BMC Psychiatry

Table 2 Linear mixed-effects model for yearly employment outcomes (cumulative work months and incomes) in a 2-year follow-up study (N = 514)

Independent variable	Cumulative work months	P-value	Cumulative work incomes	P-value
	B (S.E.)		B (S.E.)
Symptomatic remission ^a	0.80 (0.37)*	0.029 ^a	3250.4 (1175.8)*	0.001 ^a
Age	0.00 (0.01)	0.91	−87.3 (46.9)	0.09
Gender	−0.10 (0.28)	0.71	− 132.6 (926.9)	0.95
Male (ref. level)
Education (yrs.)	0.06 (0.04)	0.18	184.4 (140.8)	0.31
Antipsychotics type		0.43		0.81
FGAs	0.27 (0.34)		343.2 (1129.0)
NC-SGAs	0.32 (0.33)	0.33	204.8 (1073.5)	0.93
Clozapine (ref. level)
Defined daily dose of antipsychotics	0.32 (0.24)	0.18	− 762.9 (791.9)	0.56
MMSE	0.01 (0.02)	0.67	13.3 (62.9)	0.85
PSP	0.03 (0.02)*	0.04	9.1 (50.0)	0.87
Time effect
Time 1 (first yr.)	0.33 (0.15)*	0.02	1537.5 (1765)	0.29
Time 2 (second. yr.) (ref. level)
Initial employment types
Hospital-based workshop	−8.44 (0.34)*	0.001	−11,312.9 (1116.2)*	0.001
Sheltered	0.56 (0.44)	0.19	− 6394.8 (1394.2)*	0.001
Supported (ref. level)

Note
^a Adjusted for multiple testing correction using the Holm Bonferroni method, which revealed cumulative work months and cumulative work incomes were all significantly associated with symptomatic remission (the p-value remained significant and unchanged)
^a Concerning the steps of conducting Holm Bonferroni method, please see Additional file 1
FGA first-generation antipsychotics (typical antipsychotics); NC-SGAs non-clozapine atypical antipsychotics; MMSE mini-mental state examination; PSP personal and social performance
Age, sex, education, antipsychotic types, antipsychotic dose, MMSE and initial employment type were controlled for
* p < 0.05; B estimated coefficient; S.E. standard error

ISSN: 1471-244X